derivatized amino acids were carried out using the above conditions.
Fmoc protection of natural bilaid A (1a).
A sample of 1a (500 µg, 1 eq.) was dissolved in 1:1 H2O:THF (500 µL). To this was added NaHCO3 (92 µg, 1.1 eq.) in H2O (10 µL), N-(9-fluorenylmethoxycarbonyloxy)succinimide (371 µg, 1.1 eq.) in 1:1 H2O:THF (100 µL) and the reaction sealed and left at 30 ºC for 19 h. All solvents were removed under N2 gas, and the sample dissolved in MeOH (250 µL). An aliquot (100 µL) was purified by analytical HPLC (2  50 µL injections, Zorbax Eclipse C8 column, 250  9.4 mm, 5 µm, 1 mL/min with a gradient elution of 10 -100% MeCN / H2O (+ isocratic 0.01% TFA)/MeCN over 15 min, with the product eluting at 12.7 min.
Acid hydrolysis and Marfey's analysis on Fmoc protected bilaid A (1a).
To the purified protected peptide was added 6 M HCl (200 µL) and the resulting solution heated at 110 ºC for 19 h. The HCl was removed under N2 gas. Marfey's reaction was carried out in an identical manner as for 1. HPLC analysis was as for 1a. with co-injection studies confirming that bilaid A co-eluted 1a/1b. Chiral HPLC was used to resolve 1a (6.8 mins) from 1b (5.7 mins) and unambiguously confirm the structure for bilaid A (1a) as shown in Fig. 1 . and was added to the reaction vessel. The mixture was shaken for 10 min and a ninhydrin test was performed to calculate the coupling yield. This test was repeated after each coupling. After completion of the assembly, the terminal Fmoc group was removed as described above, the resin washed with DMF followed by DCM and dried under nitrogen.
Structure elucidation of bilaid

Isolation of bilaids B and C (2a and 3a):
The peptide was cleaved from the resin by shaking with 10 mL of cleavage mixture (95% TFA / 5% water) for 2 h. TFA was evaporated under N2 gas.
Purification of synthetic peptide acids from solid phase synthesis: Reaction products
for the synthetic peptides, were purified by preparative HPLC ( for each test peptide at a concentration of 10 μM.
Brain slice electrophysiology: Brain slices containing locus coeruleus LC neurons were prepared from male Sprague Dawley rats (4-6 weeks) as described previously. 5 Briefly, male rats were anesthetized with isoflurane and decapitated. The brain was dissected and mounted in a vibratome chamber (Leica biosystem, VT100, Wetzlar, Germany) in order to prepare horizontal brain slices (280 μm). Slices were cut and stored in warm (34°C) artificial cerebrospinal fluid (ACSF) containing the following (in mM): 125 NaCl, 2.5 KCl, 
Expression of GRK2-YFP and β-arrestin 2-HA in AtT20
GRK2-YFP and β-arrestin 2-HA plasmids were transfected using TurboFect (Thermo 
Bias calculation and statistics:
Agonist concentration response curves were fitted to a three-parameter concentration response curve, a logistic function with constrained slope of 1, in GraphPad Prism 7 producing estimates of curve location (EC50) and asymptote (Emax).
As basal activity was subtracted in all pathways the bottom of the curve was constrained to 0.
The de facto standard for quantifying agonist affinity and efficacy to accurately determine biased signaling is the operational model of agonism. 8, 9 Agonist concentration response data for each pathway was fitted to the operational model. Maximal effect in the system was defined by the reference full-agonist met-enkephalin and the slope of the transducer curve constrained to one. Efficacy (τ) and affinity (KA) estimates were produced from the curve fit for test agonists endomorphin-2, bilorphin and morphine. log(τ/KA) values for each agonist were normalized by subtraction of the reference agonist met-enkephalin log(τ/KA) value within each pathway to produce Δlog(τ/KA). Subtraction across pathways produced ΔΔlog(τ/KA), a normalized estimated of each agonist's signaling bias. Previous papers on the operational model have advocated application of pooled variance in order to increase the power of these comparisons. 10 This approach is not suitable here, or in any situation with variable curve fit quality, due to the very low signaling efficacy of the biased agonists producing much larger error for the fit derived parameters and invalidating the assumptions of pooled variance (Supplementary Table 2 ). Standard error of the linear combinations of parameters was therefore propagated exactly under standard rules. 11 Poor curve fit due to low signaling efficacy reduced the power of the ΔΔlog(τ/KA) approach generally and prevented confident interpretation of bias estimates from this approach (Fig.   S2E ).
In cases where all test agonists are partial compared to the reference agonist efficacy alone has been used to quantify bias. 12 In systems with low receptor reserve the asymptote of the logistic function, Emax, is a robust, assumption free and affinity independent estimate of efficacy that approaches the value of operational efficacy. In systems with a linear relationship between agonist occupancy and effect such as the β-arrestin pathways studied here where there is no signal amplification, Emax approximates operational efficacy, 'τ'.
Here, we normalized Emax to the reference agonist within each pathway and subtracted across comparison pathways to produce Δ normalized Emax, an efficacy measure of bias.
Observation of concentration-response curve position, which approaches operational affinity for all partial agonists presented here, across pathways measured shows bias in this instance does not appear affinity driven due to conservation of rank potency.
Degrees of freedom were calculated by first conservatively taking the lower of the two sample sizes when normalizing to met-enkephalin. In the case of Δ normalized Emax, variance across the pathways could be assumed to be equal allowing degrees of freedom to be summed. In the case of ΔΔlog(τ/KA), low efficacy in the ßpathways caused heterogeneity of variance and degrees of freedom was approximated using the Welch-
Satterwaite equation (ISO/IEC Guide to Uncertainty in Measurement).
Bias of each agonist, in both Δ normalized Emax and ΔΔlog(τ/KA) calculations, was tested by a one-way t-test to 0, the value of the reference agonist. The bias of bilorphin was then compared to morphine using a two-sample t-test, equal or unequal variance as appropriate.
All comparisons were multiplicity adjusted using the Holm-Sidak ranking method (GraphPad Prism 7) within each pair of pathways examined.
Molecular dynamics
Generation of peptide conformations: The 3D conformers of bilorphin and endomorphin-2 (EM2) were built in Chimera. 13 Two endomorphin-2 conformers were used, with the Tyr1-Pro2 peptide bond modelled as either the cis or trans isomer, and treated as separate ligands for MD simulation and docking. Peptides were protonated at the N-terminal tyrosine and parameterized with Antechamber and the general Amber force field. 14, 15 To account for the flexibility of the tetrapeptides, conformer generation was performed by running 1 μs MD simulations of each peptide in explicit solvent (0.15 M NaCl and TIP3P water) under the Amber ff14SB force field. These trajectory data were analyzed with cpptraj 16 to extract 10,000 conformations for each peptide to use in molecular docking.
Docking of peptides to MOPr: Molecular docking was performed with the Bristol
University Docking Engine (BUDE). 17 Peptides were docked to an inactive MOPr model obtained from the x-ray crystal structure of the antagonist-bound MOPr (PDB: 4DKL). 18 The protein was prepared in Insight II (Accelrys) as follows; ligands and the T4 lysozyme MD simulations: Each peptide-MOPr complex was embedded in a POPC:POPE:cholesterol lipid bilayer at a 5:5:1 ratio using the replacement method, and the simulation box (initial dimensions: 90, 110, 90 Å) solvated with TIP3P water and NaCl (150 mM), using the CHARMM-GUI software. 19 Amber parameter topology and coordinate files were prepared in LEaP. Structures were minimized over 10,000 steps, then the system was heated under constant volume and pressure with lipids restrained, from 0 K to 100 K over 5 ps, and then from 100 K to 310 K over 100 ps. Trajectories were visualized in VMD, 22 analysis was performed using cpptraj, 16 Table S1 . Initial screening of bilaid-related peptides 
